“To be honest it came out of the blue: it was a complete shock,” says Ben Jackson of the lawsuit that landed on US biotech company Myriad Genetics’ doormat in May 2009. Led by the American Civil Liberties Union (ACLU), the suit claimed two of the company’s prized gene patents are invalid, unconstitutional and stifle diagnostic testing and research.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
15 April 2013 Myriad Genetics will deliver an oral argument at the US Supreme Court today defending its patents covering isolated human gene sequences linked to breast and ovarian cancer.
15 April 2013 Myriad Genetics will deliver an oral argument at the US Supreme Court today defending its patents covering isolated human gene sequences linked to breast and ovarian cancer.
15 April 2013 Myriad Genetics will deliver an oral argument at the US Supreme Court today defending its patents covering isolated human gene sequences linked to breast and ovarian cancer.